Shilpa Medicare Limited (NSE:SHILPAMED)
722.00
+40.75 (5.98%)
Apr 24, 2025, 3:30 PM IST
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 3.19B INR in the quarter ending December 31, 2024, with 11.46% growth. This brings the company's revenue in the last twelve months to 12.49B, up 11.03% year-over-year. In the fiscal year ending March 31, 2024, Shilpa Medicare had annual revenue of 11.53B with 9.64% growth.
Revenue (ttm)
12.49B
Revenue Growth
+11.03%
P/S Ratio
5.02
Revenue / Employee
12.40M
Employees
1,007
Market Cap
62.71B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
Mar 31, 2021 | 9.02B | -66.41M | -0.73% |
Mar 31, 2020 | 9.08B | 1.75B | 23.79% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Shilpa Medicare News
- 7 days ago - Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement - Business Upturn
- 15 days ago - Shilpa Medicare gets USFDA approval for Varenicline tablets for smoking cessation - Business Upturn
- 21 days ago - Shilpa Medicare’s partner Amneal launches BORUZU in US - Business Upturn
- 5 weeks ago - Shilpa Medicare subsidiary signs exclusive deal with Switzerland-based mAbTree Biologics AG - Business Upturn
- 5 weeks ago - Shilpa Medicare’s subsidiary clears USFDA inspection with zero observations for second consecutive time - Business Upturn
- 6 weeks ago - Shilpa Medicare subsidiary receives one observation from USFDA for Unit-1 facility in Raichur - Business Upturn
- 2 months ago - Shilpa Medicare secures CDSCO approval for Phase 3 clinical trial - Business Upturn
- 2 months ago - Shilpa Medicare Q3 results: Revenue up 11% YoY to Rs 319 crore, Net Profit up 595% YoY - Business Upturn